ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Small Cell Lung Carcinoma
Carcinoma
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis

Lung Cancer trials near Hanyang, Seoul, KOR:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Seoul, South Korea and 83 other locations

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10)

to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 2

Arcus Biosciences
Arcus Biosciences

Seoul, South Korea and 96 other locations

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seoul, South Korea and 84 other locations

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...

Enrolling
Lung Cancer
EGFR Mutation-Related Tumors
Drug: BG-60366

Phase 1

BeiGene
BeiGene

Seoul, Seoul Teugbyeolsi, South Korea and 26 other locations

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: JDQ443
Drug: docetaxel

Phase 3

Novartis
Novartis

Seongnam-si, Gyeonggi-do, South Korea and 52 other locations

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Seoul, Songpa-gu, Korea, Republic of and 30 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, South Korea and 210 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 122 other locations

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer...

Active, not recruiting
Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Drug: Paclitaxel
Drug: BNT327 Dose Level 2 (DL2)

Phase 2

BioNTech
BioNTech

Seoul, South Korea and 64 other locations

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The aims of this study are to see how safe an...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: BNT116

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Seoul, Gyeonggi, Korea, Republic of and 51 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems